TScan Therapeutics ( (TCRX) ) has shared an announcement.
TScan Therapeutics has announced promising results from its ALLOHA Phase 1 trial, showing that TSC-100 and TSC-101 therapies could significantly reduce relapse in patients with acute leukemias and myelodysplastic syndromes post-transplant. The study, which enrolled 38 patients, demonstrated improved event-free survival rates for those receiving the treatment, with the therapies well-tolerated and no dose-limiting toxicities observed. Encouraged by the data, TScan plans to launch a pivotal trial in 2025, potentially expanding its market with increased use of reduced intensity conditioning and haploidentical donors.
See more insights into TCRX stock on TipRanks’ Stock Analysis page.